External beam radiotherapy is consolidated like radical treatment for localized and locally advanced prostate cancer. In addition, more and more studies show its effectiveness as much in postoperative as in salvage intention. Before choosing a therapeutic option, it is important to know the baseline state of the patients and the possible side effects of the treatment. In that way, different questionnaires and toxicity scales are at our disposal. Acute effects, during the treatment and the following weeks, are due to irritating and inflammatory symptoms. Chronic toxicity, months or years after radiotherapy, are consequence of the fibrosis and ischemia, as well as of alterations at the myogenic and neuronal level. Urinary incontinence is a relatively uncommon symptom among patients who have been treated with radiotherapy. But, due to the profound impact on the quality of life of our patients, it is necessary to identify patients at higher risk. Antecedent of transurethral resection of the prostate, before or after the irradiation, and severity of acute genitourinary toxicity increase the risk of developing incontinence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4321/s0004-06142009001000006 | DOI Listing |
Int Urol Nephrol
January 2025
Department of Urology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Objective: To evaluate the outcomes and efficacy of robot-assisted radical prostatectomy (RARP) using the Versius robotic surgical system, aiming to provide comprehensive data on perioperative outcomes, postoperative recovery, and complications.
Patient And Methods: All cases of RARP using the CMR Versius platform performed at Cairo University Hospital over a two-year period were enrolled in this study. All patients had pathologically confirmed prostate cancer in both localized and locally advanced stages.
Med Oncol
January 2025
Department of In Vivo Pharmacology, TCG Lifesciences Pvt. Ltd, BN 7, Sector V, Salt Lake City, Kolkata, West Bengal, 700091, India.
Cancer is a major global health issue that is usually treated with multiple therapies, such as chemotherapy and targeted therapies like immunotherapy. Immunotherapy is a new and alternative approach to treating various types of cancer that are difficult to treat with other methods. Although immune checkpoint inhibitors have shown promise for long-term efficacy, they have limited effectiveness in common cancer types such as breast, prostate, and lung.
View Article and Find Full Text PDFClin Exp Metastasis
January 2025
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Oligorecurrent prostate cancer (PCa) can be treated with metastasis-directed therapy (MDT), which may be performed using radioguided surgery (RGS) as an experimental approach. These procedures have shown promising outcomes, largely due to the high lesion detection rate of positron emission tomography/computed tomography (PET/CT). We present a case series of patients who underwent RGS following robot-assisted radical prostatectomy (RARP).
View Article and Find Full Text PDFFuture Oncol
January 2025
uHuntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA.
Eur Urol Open Sci
February 2025
Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Background And Objective: PARP inhibitor (PARPi) treatment is an effective option for patients with metastatic castration-resistant prostate cancer (mCRPC). There are few data on the cardiovascular and thromboembolic safety of these agents in mCRPC, as cardiovascular and thromboembolic adverse events (AEs) are uncommon. Our aim was to analyze the incidence and risk of major adverse cardiovascular events (MACEs), thromboembolic events, and hypertension with PARPi therapy in mCRPC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!